drugset / Trial / NCT04383275
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open label, phase II study evaluating the efficacy and safety of trastuzumab combined with oral chemotherapy or endocrine therapy in patients with HER-2 positive stage I breast cancer.
Timeline
- Start
- 2021-08-23
- Primary completion
- 2025-05-15
- Completion
- 2027-05-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anastrozole | Other / unclassified | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Exemestane | Small molecule | — | — |
| Subject | Letrozole | Other / unclassified | — | — |
| Subject | Tamoxifen | Small molecule | — | — |
| Subject | Toremifene | Small molecule | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |